These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 9249251

  • 21. Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate.
    Tian G, Rocque WJ, Wiseman JS, Thompson IZ, Holmes WD, Domanico PL, Stafford JA, Feldman PL, Luther MA.
    Biochemistry; 1998 May 12; 37(19):6894-904. PubMed ID: 9578576
    [Abstract] [Full Text] [Related]

  • 22. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM, Barnes PJ, Giembycz MA.
    Cell Biochem Biophys; 1998 May 12; 29(1-2):179-201. PubMed ID: 9631245
    [Abstract] [Full Text] [Related]

  • 23. Selective type IV phosphodiesterase inhibitors prevent IL-4-induced IgE production by human peripheral blood mononuclear cells.
    Coqueret O, Boichot E, Lagente V.
    Clin Exp Allergy; 1997 Jul 12; 27(7):816-23. PubMed ID: 9249275
    [Abstract] [Full Text] [Related]

  • 24. A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
    Chambers RJ, Abrams K, Castleberry TA, Cheng JB, Fisher DA, Kamath AV, Marfat A, Nettleton DO, Pillar JD, Salter ED, Sheils AL, Shirley JT, Turner CR, Umland JP, Lam KT.
    Bioorg Med Chem Lett; 2006 Feb 12; 16(3):718-21. PubMed ID: 16263279
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model.
    Hamamoto M, Suga M, Nakatani T, Takahashi Y, Sato Y, Inamori S, Yagihara T, Kitamura S.
    Eur J Cardiothorac Surg; 2004 May 12; 25(5):833-8. PubMed ID: 15082290
    [Abstract] [Full Text] [Related]

  • 28. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines.
    Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, LaRosa GJ, Rao P, Ponath PD, Baggiolini M, Dahinden CA.
    J Clin Invest; 1997 Sep 01; 100(5):1137-43. PubMed ID: 9276730
    [Abstract] [Full Text] [Related]

  • 29. Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
    Ikemura T, Schwarze J, Makela M, Kanehiro A, Joetham A, Ohmori K, Gelfand EW.
    J Pharmacol Exp Ther; 2000 Aug 01; 294(2):701-6. PubMed ID: 10900250
    [Abstract] [Full Text] [Related]

  • 30. Characterization of CHO-K1 cells stably expressing PDE-IV enzymes. Whole-cell cAMP determinations vs broken-cell enzymatic assays.
    Pon DJ, Plant M, Tkach J, Boulet L, Muise E, Allen RA, Rodger IW.
    Cell Biochem Biophys; 1998 Aug 01; 29(1-2):159-78. PubMed ID: 9631244
    [Abstract] [Full Text] [Related]

  • 31. Membrane-bound eotaxin-3 mediates eosinophil transepithelial migration in IL-4-stimulated epithelial cells.
    Yuan Q, Campanella GS, Colvin RA, Hamilos DL, Jones KJ, Mathew A, Means TK, Luster AD.
    Eur J Immunol; 2006 Oct 01; 36(10):2700-14. PubMed ID: 16983721
    [Abstract] [Full Text] [Related]

  • 32. Phosphodiesterase type 4 inhibitor reduces the retention of polymorphonuclear leukocytes in the lung.
    Sato Y, Sato S, Yamamoto T, Ishikawa S, Onizuka M, Sakakibara Y.
    Am J Physiol Lung Cell Mol Physiol; 2002 Jun 01; 282(6):L1376-81. PubMed ID: 12003795
    [Abstract] [Full Text] [Related]

  • 33. Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
    Torphy TJ, Barnette MS, Hay DW, Underwood DC.
    Environ Health Perspect; 1994 Dec 01; 102 Suppl 10(Suppl 10):79-84. PubMed ID: 7705312
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Interactions between eotaxin and interleukin-5 in the chemotaxis of primed and non-primed human eosinophils.
    Costa GG, Silva RM, Franco-Penteado CF, Antunes E, Ferreira HH.
    Eur J Pharmacol; 2007 Jul 02; 566(1-3):200-5. PubMed ID: 17368616
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of eosinophil survival by a selective inhibitor of phosphodiesterase 4 via the induction of apoptosis.
    Wang W, Masu K, Tamura G, Suzuki K, Ohwada K, Okuyama K, Shirato K, Takayanagi M, Ohno I.
    Biol Pharm Bull; 2005 Mar 02; 28(3):515-9. PubMed ID: 15744080
    [Abstract] [Full Text] [Related]

  • 37. Human eotaxin induces eosinophil-derived neurotoxin release from normal human eosinophils.
    El-Shazly A, Masuyama K, Nakano K, Eura M, Samejima Y, Ishikawa T.
    Int Arch Allergy Immunol; 1998 Sep 02; 117 Suppl 1():55-8. PubMed ID: 9758899
    [Abstract] [Full Text] [Related]

  • 38. Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils.
    Stubbs VE, Schratl P, Hartnell A, Williams TJ, Peskar BA, Heinemann A, Sabroe I.
    J Biol Chem; 2002 Jul 19; 277(29):26012-20. PubMed ID: 11980903
    [Abstract] [Full Text] [Related]

  • 39. The effect of pharmacological PI3Kγ inhibitor on eotaxin-induced human eosinophil functions.
    Saito Y, Takeda M, Nishikawa J, Konno Y, Tamaki M, Itoga M, Kobayashi Y, Moritoki Y, Ito W, Chihara J, Ueki S.
    Pulm Pharmacol Ther; 2014 Apr 19; 27(2):164-9. PubMed ID: 24333185
    [Abstract] [Full Text] [Related]

  • 40. Effects of solubilization and vanadate/glutathione complex on inhibitor potencies against eosinophil cyclic AMP-specific phosphodiesterase.
    Souness JE, Maslen C, Scott LC.
    FEBS Lett; 1992 May 11; 302(2):181-4. PubMed ID: 1321725
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.